Against the backdrop of the current high incidence of cardiovascular diseases, Sacubitril/Valsartan Sodium Tablets (Entresto) is an innovative drug for the treatment of chronic heart failure and hypertension. Its standardized use and guarantee of genuine products are particularly crucial. Due to the complex composition and special mechanism of action of this drug, patients must obtain it through legal channels and master necessary anti-counterfeiting knowledge.
Purchasing Channels for Sacubitril/Valsartan Sodium Tablets (Entresto)
Overseas Purchasing
Patients can choose to consult and purchase the drug at hospital pharmacies or formal drugstores in countries or regions where Sacubitril/Valsartan Sodium Tablets have been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budgets and plans in advance before purchasing.
Purchasing through Medical Service Institutions
Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions can usually provide legal import channels and offer professional consultation and guidance.
Precautions for Sacubitril/Valsartan Sodium Tablets (Entresto)
Pre-Medication Contraindication Screening
Patients allergic to any component of the drug.
Patients who are currently using angiotensin-converting enzyme inhibitors (such as enalapril, captopril, etc.) or have discontinued such drugs for less than 36 hours.
Patients with a history of angioedema (including hereditary and drug-induced types).
Patients with severe hepatic impairment (Child-Pugh Class C).
Pregnant women and lactating women.
Specifications for Using Special Dosage Forms
Pediatric Granules: All granules inside the capsule must be taken out for administration; swallowing the capsule shell whole is strictly prohibited.
It is necessary to ensure that each dose is a complete unit (the 12.5mg specification contains 4 micro-tablets, and the 31.25mg specification contains 10 micro-tablets), and divided doses are not allowed.
Clinical Monitoring Requirements
During the initial medication period and dose escalation stage, blood pressure, serum potassium levels, and renal function must be closely monitored.
Combined use with drugs such as atorvastatin may increase the blood concentration of this drug.
Combined use with potassium-sparing diuretics (such as spironolactone, eplerenone, etc.) requires monitoring of electrolyte balance.
Pre-Operative Intervention
Medication should be suspended 24 hours before surgery to avoid refractory hypotension during anesthesia.
Authentication of Sacubitril/Valsartan Sodium Tablets (Entresto)
Verification of Packaging Information
The outer box must clearly indicate the manufacturer information of "Shionogi & Co., Ltd.".
Verify that the approval number matches the drug specification.
Comparison of Physical Characteristics of Tablets
50mg Tablets: Blue-purple oval film-coated tablets, with a major diameter of 13.1mm and the identification code "NVRLZ".
100mg Tablets: Pale yellow oval scored tablets, with the identification code "L".
200mg Tablets: Pinkish-white oval coated tablets, with a major diameter of 15.1mm and the identification code "NVRL11".
Anti-Counterfeiting Key Points for Granules
12.5mg Specification: The capsule cap is marked with white "04", and the bottle body is marked with "NVR".
31.25mg Specification: The capsule cap is marked with yellow "10", and the bottle body is marked with "NVR".
Official Verification Channels
Enter the approval number in the "Drug Query" section on the official website of the National Medical Products Administration.
Scan the drug traceability code on the drug packaging box to verify the circulation record.
